Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
EIKN compared with AKTS: revenue, margins and what each company keeps, and the suppliers and customers both name
EIKN
Eikon Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
AKTS
Aktis Oncology, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
EIKN
Eikon Therapeutics, Inc.
vs
AKTS
Aktis Oncology, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
EIKN: latest quarter not drawable. AKTS: latest quarter is a loss; flow not drawable.
Method
›
EIKN
Eikon Therapeutics, Inc.
Change
5.68
▲
+7.01%
· post 5.60
Mkt cap
$287.5M
Revenue
—
AKTS
Aktis Oncology, Inc.
Change
14.58
▼
−8.45%
· post 14.59
Closed
Nov 2 '26
Mkt cap
$806.8M
Revenue
$3M
Q2 FY26
vs
Compare
Closed
Nov 2 '26
EIKN
Eikon Therapeutics, Inc.
vs
AKTS
Aktis Oncology, Inc.
5.68
▲
+7.01%
post 5.60
Price
14.58
▼
−8.45%
post 14.59
$287.5M
Mkt cap
$806.8M
—
Revenue
$3M
Q2 FY26
Change
Change
EIKN
5.68
▲
+7.01%
vs
AKTS
14.58
▼
−8.45%
Closed
Nov 2 '26
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
EIKN, solid
AKTS, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only EIKN
4
MRK
MSD International Business GmbH
supplier
—
Impact Therapeutics (Shanghai)
unlisted
supplier
—
Seven and Eight Biotherapeutics
unlisted
supplier
—
Superb Wisdom
unlisted
supplier
Shared
0
No disclosed counterparties: AKTS.
Only AKTS
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR